Ionic Transport Assays, Inc. is a contract research organization located in St Louis, MO. Since 2011, Ionic Transport Assays has performed multiple assays for customers on human induced pluripotent stem cell cardiomyocytes (hIPSC–CM). This work is directed to meet the challenges of the Safety Pharmacology Comprehensive in vitro Proarrhythmia Assessment (CiPA) proposed by the FDA for new drug development. Ionic Transport Assays uses the SpectraMax® i3 Multi-Mode Microplate Reader from Molecular Devices to measure intracellular calcium fluoresence as a marker of cardiac contraction, electrophysiology and toxicity in hIPSC cardiomyocytes. This high throughput pre-clinical testing uses relevant human tissue to identify compounds with cardiac issues early in the drug development pipeline, saving customers’ time and money.